Williams adds that new studies are uncovering benefits involving other chronic diseases, such as heart disease, Type 1 diabetes and polycystic ovary syndrome (PCOS)
(2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Chao Liao, et al
Most do not find differences in sweet taste perception between individuals with and without obesity
Will keep ordering Great experience from start to finish
However, findings from trials like those of TRIUMPH-1 could open doors for its eventual approval and accessibility, allowing weight loss specialists to add it to their repertoire of medical interventions
Developer: Eli Lilly and Company | Administration in Trials: Once-weekly subcutaneous injection First successful Phase 3 trial (TRIUMPH-4, topline Dec 2025): Up to 28.7% average body weight loss at 68 weeks (highest dose) in adults with obesity/overweight and knee osteoarthritis
